EFPIA Picks Holes With EMA's Revised Guidance On Risk Management Plans
This article was originally published in SRA
The European Federation of Pharmaceutical Industries and Associations has welcomed most of the changes that the European Medicines Agency has proposed making to its guideline on risk management plans (RMPs), saying that the revisions would help remove "several redundancies present in the current version" of the guidance. However, EFPIA has significant concerns over certain other parts of the revised guideline, such as the rewording of certain sections that it believes could be misinterpreted by those enforcing the guideline and create confusion.
You may also be interested in...
The European Medicines Agency is finalizing changes to its eagerly-awaited guidance on risk management plans, which aims to simplify the submission and maintenance of RMPs by drug companies. The EMA has fine-tuned the document to address some misunderstandings within the industry and is currently deciding on the transition plans for implementing the new requirements.
The European Commission reports that new regulatory tools made available under the revised pharmacovigilance legislation have allowed drug safety issues to be detected and acted upon more rapidly, and that further improvements to the system are in the pipeline.
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.